

# CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED

(Incorporated in the Republic of Singapore)  
(Company Registration No. 200505118M)

---

## PROPOSED RENOUNCEABLE AND NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE – LISTING AND QUOTATION OF 80,309,351 ADDITIONAL OUTSTANDING WARRANTS

---

*Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings as ascribed to them in the Company's offer information statement dated 3 October 2017 in relation to the proposed renounceable and non-underwritten rights cum warrants issue of up to 10,107,788,721 new ordinary shares in the capital of the Company with up to 10,107,788,721 free detachable warrants (the "Offer Information Statement") and the announcements released by the Company on 11 October 2017, 13 October 2017 and 21 October 2017 (the "Previous Announcements"). Any reference to the time of day and date herein shall be a reference to Singapore time and date, respectively.*

### **LISTING AND QUOTATION OF ADDITIONAL OUTSTANDING WARRANTS**

1. The Company refers to the Warrants Adjustment and is pleased to announce that 80,309,351 Additional Outstanding Warrants (excluding foreign entitlement) have been allotted and issued by the Company pursuant to the Rights cum Warrants Issue today. The Company did not issue the Additional Outstanding Warrants to Warrantholders with registered addresses outside of Singapore as at 24 October 2017 as disclosed in the Previous Announcement of 13 October 2017.
2. The Additional Outstanding Warrants will be listed and quoted on Catalist on 1 November 2017, and the trading of the Additional Outstanding Warrants on Catalist under the book-entry (scripless) settlement system will commence with effect from 9.00 a.m. on the same date.
3. Following the allotment and issue of 80,309,351 Additional Outstanding Warrants, the number of Outstanding Warrants has increased from 66,179,592 Outstanding Warrants to 146,488,943 Outstanding Warrants.

**By Order of the Board**  
**31 October 2017**

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

*This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Lance Tan, Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).*